Highest-materiality recent filing
3M Q2 adjusted EPS $2.40 beats; raises FY2026 guidance to $8.80-$8.95
GAAP EPS $1.78, up 33% YoY; GAAP sales $6.5B, up 2.4%.
3M subsidiary secures $1.43B term loan and $200M revolver to fund Madison Safety acquisition
$1.43B term loan facility and $200M revolving credit facility; maturity 364 days after closing with possible 12-month extension.
3M Q1 adjusted EPS $2.14 (+14% YoY); reiterates FY2026 guidance
GAAP EPS $1.23 (down 40% YoY); adjusted EPS $2.14 (up 14% YoY).
3M reports Q4 adjusted EPS $1.83 (+9% YoY); FY2026 guidance $8.50-$8.70
Q4 GAAP EPS $1.07 vs $1.33 YoY; adjusted EPS $1.83 (+9% YoY) on adjusted sales $6.0B (+3.7%).
3M Q3 adjusted EPS $2.19 beats; raises full-year EPS guidance to $7.95-$8.05
GAAP sales $6.5B (+3.5% YoY); adjusted sales $6.3B with organic growth 3.2%.
3M Q2 adjusted EPS $2.16 (+12% YoY), raises FY2025 EPS guidance to $7.75-$8.00
GAAP EPS $1.34, down 38% YoY; adjusted EPS $2.16, up 12% YoY.
3M agrees to $285M PFAS settlement with New Jersey, subject to court approval
Pre-tax charge of ~$285M in Q2 2025; $210M for Chambers Works (payments 2026-2033) and $75M for statewide PFAS claims (payments 2030-2050).
GAAP sales $6.0B (-1.0% YoY); adjusted sales $5.8B (+0.8% YoY); adjusted organic sales +1.5%.
3M sets medium-term targets: ~25% op margin by 2027, $10B+ shareholder returns
Medium-term outlook: organic sales growth to outperform macro; operating margin ~25% by 2027.
CEO Bill Brown to succeed Mike Roman as 3M Chairman; Roman retires; David Bozeman joins board
Michael F. Roman retires as Executive Chairman and Director effective March 1; remains Executive Advisor until May 1, 2025.
Q4 GAAP EPS $1.33, up 17% YoY; adjusted EPS $1.68, down 2% YoY.
3M Q3 adjusted EPS $1.98 (+18% YoY); raises FY2024 adjusted EPS guidance to $7.20-$7.30
GAAP EPS from continuing operations $2.48 (up 154% YoY); adjusted EPS $1.98 (up 18% YoY).
3M appoints Anurag Maheshwari as CFO effective September 1, 2024
Anurag Maheshwari named EVP & CFO, starting Sept 1; previously CFO of Otis Worldwide.
3M Q2 adjusted EPS $1.93 (+39% YoY), raises FY2024 EPS guidance to $7.00-$7.30
GAAP EPS $2.17 vs ($12.94) prior year; operating margin 20.3%.
3M CFO Monish Patolawala to resign effective July 31, 2024
Monish Patolawala, President and CFO, resigns effective July 31, 2024 to pursue another opportunity.
3M transfers $2.5B in pension obligations to Met Tower Life; expects $0.8-$0.9B non-cash charge
Transfers ~$2.5B in defined benefit pension obligations and related plan assets for ~23,000 U.S. retirees.
3M Q1 adj. EPS $2.39 (+21% YoY), Solventum spin complete, Bill Brown named CEO
Q1 sales $8.0B (-0.3% YoY); GAAP EPS $1.67 (-5% YoY); adj. EPS $2.39 (+21% YoY).
3M completes spin-off of health care business Solventum; distribution ratio 1:4
On April 1, 2024, 3M distributed 80.1% of Solventum shares to 3M stockholders.
3M completes spin-off of health care business; Solventum begins trading as SOLV
One Solventum share issued for every 4 MMM shares held as of March 18, 2024 record date.
3M appoints William Brown as CEO effective May 1, 2024; Roman becomes Executive Chairman
William M. Brown, former CEO of L3Harris Technologies, appointed 3M CEO effective May 1, 2024.
3M board approves spin-off of Health Care business as Solventum; distribution April 1, 2024
Record date March 18, 2024; shareholders receive 1 Solventum share for every 4 MMM shares.
3M subsidiary Solventum issues $6.9B in senior notes to fund health care spin-off
Solventum issued $6.9B aggregate principal across six tranches: 5.45% due 2027, 5.40% due 2029, 5.45% due 2031, 5.60% due 2034, 5.90% due 2054, 6.00% due 2064.
3M elects to pay $1B cash for earplug settlement; participation exceeds 98% threshold
3M amends settlement to irrevocably elect cash for the $1 billion payment option, instead of stock.
3M Q4 adjusted EPS $2.42 beats $2.18 YoY; FY 2024 outlook $9.35-$9.75
Q4 GAAP EPS $1.70 (vs $0.98); adjusted EPS $2.42 (vs $2.18), up 11% YoY.
3M Q3 adj EPS $2.68 beats, raises FY outlook; $4.2B charge from Combat Arms settlement
GAAP loss per share $3.74 includes $4.2B pre-tax charge for Combat Arms earplug settlement.
3M idles PFAS production at Zwijndrecht after self-reporting to Flemish regulators
3M Belgium idled all PFAS manufacturing at its Zwijndrecht facility after self-reporting emissions data to Flemish authorities.
3M amends credit agreement to accommodate $6.01B earplug settlement charges
Amendment to $4.25B revolving credit agreement allows add-back of CAE settlement charges for EBITDA calculation.
3M settles Combat Arms Earplug litigation for $6.01B; records $4.2B Q3 charge
3M to pay $6.01B ($5.01B cash, $1B stock) from 2023-2029 to resolve all Combat Arms Earplug claims.
3M appoints Bryan Hanson as Health Care CEO, Carrie Cox as chair, Patolawala as President & CFO
Bryan Hanson (ex-Zimmer Biomet CEO) named CEO of 3M Health Care Business Group effective Sept 1, 2023; will lead independent health care company post-spin.
3M Q2 GAAP loss of $12.35/sh from $10.3B PFAS charge; raises adj. EPS view to $8.60-$9.10
GAAP EPS loss of $12.35 vs prior-year EPS of $0.14; includes $10.3B pre-tax charge for PFAS PWS settlement.
3M amends credit agreement to add back up to $12.5B PFAS settlement charges from EBITDA
Amendment allows exclusion of charges tied to $10.5B-$12.5B proposed PFAS drinking water class-action settlement from EBITDA calculation.
3M to pay up to $12.5B to resolve PFAS drinking water claims from U.S. public water systems
Settlement resolves drinking water PFAS claims by U.S. public water systems; total nominal value $10.5B-$12.5B payable 2024-2036.
GAAP EPS $1.76 (down from $2.26); adjusted EPS $1.97 (down from $2.63).
On June 5, 2026, the 3M Company (“3M”) Board of Directors (“Board”) elected Jennifer W. Rumsey to 3M’s Board and appointed Ms. Rumsey to the Science, Technology and Sustainability Committee of the Board, each effective June 5, 2026.
Peter Gibbons, Group President, Enterprise Supply Chain, has announced his intention to retire from 3M Company, effective April 2, 2025.
the Board of Directors of the Company has appointed Anurag Maheshwari as the Company’s Executive Vice President and Chief Financial Officer, effective September 1, 2024.
Monish Patolawala, President and Chief Financial Officer, has announced his intention to resign f rom 3M Company, effective July 31, 2024.
appointed Michael F. Roman as executive chairman of the Board of Directors, also effective May 1, 2024
appointed William M. Brown chief executive officer, effective May 1, 2024
3M Company (the “Company”) announced today that, in conjunction with the planned spin-off of the Company’s Health Care Business, Jeff Lavers, group president, Health Care Business Group, will depart from the Company, effective December 1, 2023.
On November 6, 2023, the Board of Directors of 3M Company (the “Company”) elected Thomas Sweet to the Company’s Board of Directors, effective November 6, 2023.
The Board of Directors of 3M Company (the Company) has appointed Monish Patolawala as 3M President and Chief Financial Officer of the Company, effective September 1, 2023.
On August 9, 2023, the Board of Directors of 3M Company (the “Company”) elected Audrey Choi to the Company’s Board of Directors, effective August 9, 2023.
Michael G. Vale, Group President and Chief Business and Country Officer, has been terminated for cause from 3M Company (the Company), effective May 12, 2023.
The Board of Directors of 3M Company (the Company) has appointed Michael G. Vale as the Company’s Group President and Chief Business and Country Officer, a new role on the Company’s Corporate Operations Committee, reporting to Chairman of the Board and Chief Executive Officer Michael F. Roman, effective April 25, 2023.
Max materiality 1.00 · Median 0.72 · Most common event earnings